Recently, the FDA approved two PD-1 inhibitors (nivolumab and pembrolizumab) in combination with certain types of chemotherapy for the treatment of patients with metastatic gastric cancer/metastatic HER2-positive gastric cancer. Here, ERBB2 is linked to gastric cancer.